EREG and breast carcinoma: The aberrant activity of the Ras/MAPK pathway has been identified as pivotal in the initiation and progression of breast cancer [113], miR‐21's targeting of key activators within this pathway, including ABCB1, AR, CDK6, CSF1, EREG, MKDR, among others.